2cureX receives important ISO 13485:2016 certificationENDORESIST
- Novel drug targeting antiestrogen therapy resistance: a paradigm shift in breast cancer treatment
- ENDORESIST is a translational cancer research project which aims at seizing a major market opportunity by developing SCO-101, a new drug that targets anti-estrogen resistance in breast cancer. We will deliver a clinically validated and safe drug, and a companion diagnostic tool, opening the possibility to find a big pharma buyer/partner to capitalize on the SCO-101 opportunity. ENDORESIST builds around a patient-centric approach, based on biomarker discovery and insights on mechanisms of action.
- ENDORESIST not yet started and will run for 30 month.
- Partner to the ENDORESIST project are Scandion Oncology A/S and the Department of Medical Oncology of Erasmus MC, the University Medical Center Rotterdam. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.
![](https://www.2curex.com/wp-content/uploads/scandion.jpg")
![](https://www.2curex.com/wp-content/uploads/erasmus.jpg")
![](https://www.2curex.com/wp-content/uploads/eurostars.jpg")
Project Details
Acronym:
ENDORESIST
Duration:
36 months
Start date:
Not started
Topic:
New Treatments for Anti-estrogen Resistance
Funding:
2.2 Mio EUR
Upcoming events
September 15, 2021 at 15:00 (CET)
Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.
September 23, 2021
CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark